EHC: Recognizing Von Willebrand Factor as a Critical Medicine in Bleeding Care
The European Haemophilia Consortium (EHC) recently shared a post on X:
”Von Willebrand Disease affects 1:1000 individuals and, if not recognised, may cause severe bleeding symptoms after trauma or surgery that can be life-threatening. It’s time for health systems to recognise Von Willebrand Factor as a Critical Medicine. European Medicines Agency”
Von Willebrand Disease (VWD), the most common inherited bleeding disorder, affects approximately 1 in 1,000 individuals.
When unrecognized or untreated, it can lead to serious, even life-threatening bleeding, particularly after trauma or surgical procedures.
Despite its prevalence and potential severity, VWD remains underdiagnosed and undertreated in many health systems.
There is an urgent need to designate Von Willebrand Factor (VWF) as a Critical Medicine to ensure timely diagnosis, treatment access, and improved outcomes for patients.
Recognizing VWF’s essential role in bleeding management is a key step toward better care for individuals living with VWD worldwide.
Hemostasis Today, your daily update on the waves in bleeding disorders community.
-
Jan 12, 2026, 04:51Coronary Microvascular Dysfunction and HFpEF․ Prognostic Importance and Therapeutic Insights
-
Jan 12, 2026, 04:16Wolfgang Miesbach on VTE and Cancer: A 20-Year Signal That Can’t Be Ignored
-
Jan 12, 2026, 03:54Francine Freitas Fernandes on Transvaginal US for Pelvic Venous Disorders
-
Jan 12, 2026, 02:58Jara Garcia Ugaldebere Shares STORM-PE Results: Thrombectomy Plus Anticoagulation for Acute High-Risk PE
-
Jan 12, 2026, 02:54Discover the New Blood Project․ Enhanced Search, Browsing, and Learning Resources
-
Jan 12, 2026, 02:54Can Preoperative Iron Status Predict Severe Anemia After Bariatric Surgery?
-
Jan 12, 2026, 02:27Bryce Kerlin to Impact of Advanced Hemostasis/Thrombosis Fellowship Training at Haemophilia Publication
-
Jan 12, 2026, 02:21Martin Haluzík on Compariosn of Cardiovascular Outcomes Between Semaglutide and Dulaglutide Therapies
-
Jan 12, 2026, 01:55Frank Weinz on State-of-the-Art Thromboembolism Prophylaxis